4.7 Article

Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 130, Issue 5, Pages 1049-1062

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.07.053

Keywords

Rhinitis; asthma; Allergic Rhinitis and its Impact on Asthma; allergy; GRADE

Funding

  1. Stallergenes
  2. ALK-Abello
  3. European Academy of Allergy and Clinical Immunology (EAACI)
  4. MSD
  5. Novartis
  6. Nycomed/Takeda
  7. PHADIA/Thermo Fischer
  8. 3M
  9. AstraZeneca
  10. GlaxoSmithKline
  11. Merck Frosst
  12. Altair
  13. Amgen
  14. Asmacure
  15. Boehringer-Ingelheim
  16. Genentech
  17. Pharmaxis
  18. Schering
  19. Wyeth
  20. Ache
  21. Brazilian Research Council
  22. Fundacao de Amparo a Pesquisa da Bahia
  23. Fundacao Ciencia e Tecnologia
  24. Sociedade Portuguesa de Alergologia e Immunologia Clinica
  25. Abdi Ibrahim
  26. MSD
  27. OrionPharma
  28. Nasonebs
  29. Merck
  30. McNeal
  31. Chiesi
  32. Nycomed
  33. Air Liquid Healthcare
  34. Mundipharma
  35. Almirall
  36. Kyorin
  37. Teva
  38. UK National Health Service
  39. Aerocrine
  40. AKL Ltd
  41. PREDICTA
  42. Swiss National Science Foundation
  43. MeDALL
  44. Global Allergy and Asthma European Network (GA 2LEN)
  45. Christine Kuthe Center for Allergy Research and Education
  46. Faes Farma
  47. Bial
  48. Johnson Johnson
  49. Sanofi
  50. HAD treasurer
  51. Innovative Medicine Initiative (EU)
  52. Helse Sor-Ost RHF (Southern and Eastern Norway Regional Health Authority)
  53. MEDA
  54. Alcon
  55. ISTA
  56. Thermo-Fisher
  57. Airsonett
  58. Medical Research Council
  59. Moulton Charitable Trust
  60. AB Science
  61. Canadian Institutes for Health Research
  62. AllerGen NCE
  63. Merck/Schering-Plough
  64. Circassia
  65. University Hospital
  66. Medical School of Universidad Autonoma de Nuevo Leon, Mexico
  67. Children's Research Foundation (Ireland)
  68. Danone
  69. Food Standards Agency (United Kingdom)
  70. European Union (EU)
  71. DTG
  72. Netherlands Asthma Foundation
  73. Merck-Sharp-Dohme, Mexico
  74. Allerquim Mexico
  75. Abbott
  76. Apotex
  77. HRA
  78. MedImmune
  79. Schering-Plough
  80. Proctor Gamble
  81. Sunovion (Sepracor)
  82. Phadia
  83. Servier
  84. CSC JohnsonJohnson
  85. Oxygen Plus
  86. New Medics
  87. European Respiratory Society
  88. Societe de Pneumologie de Langue Francaise Asthma
  89. Ministry of Health, Welfare, and Labor
  90. Altana
  91. Takeda
  92. UCB
  93. Uriach advisory board
  94. NAPP
  95. Royal College of GPs Clinical Champion in Allergy
  96. Agency for Healthcare Research and Quality (AHRQ)
  97. AnseII
  98. Bayer Schering
  99. OST
  100. Fujisawa
  101. IHAL
  102. Henkel
  103. Kryolan
  104. Leti
  105. MSO
  106. Procter and Gamble
  107. Sanofi-Aventis
  108. Scientific Advisory Board for the German Society for Allergy and Clinical Immunology
  109. German Federal Ministry of Consumer Protection
  110. European Centre for Allergy Research Foundation (ECARF)
  111. Medical Research Council [G1000758] Funding Source: researchfish

Ask authors/readers for more resources

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available